Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 20/20 | 0.86 |
| ▸ | KDR | P35968 | 19/20 | 0.86 |
| ▸ | LYN | P07948 | 17/20 | 0.86 |
| ▸ | SRC | P12931 | 16/20 | 0.86 |
| ▸ | INSR | P06213 | 15/20 | 0.86 |
| ▸ | HCK | P08631 | 12/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465698 | 0.93 | LCK (1.00) | LCKKDRLYNSRCINSR | |
| SCHEMBL2464173 | 0.91 | LCK (1.00) | LCKKDRLYNSRCINSR | |
| SCHEMBL14047793 | 0.90 | LCK (0.70) | LCKKDRLYNSRCINSR | |
| SCHEMBL2465699 | 0.88 | LCK (0.70) | LCKKDRLYNSRCINSR | |
| SCHEMBL2467590 | 0.86 | LCK (0.77) | LCKKDRLYNSRCINSR | |
| SCHEMBL5001947 | 0.86 | LCK (0.77) | LCKKDRLYNSRCINSR | |
| SCHEMBL2466908 | 0.86 | LCK (1.00) | LCKKDRLYNSRCINSR | |
| SCHEMBL2467634 | 0.86 | LCK (0.86) | LCKKDRLYNSRCINSR | |
| SCHEMBL14419670 | 0.85 | LYN (0.63) | LCKKDRLYNSRCINSR | |
| SCHEMBL2468678 | 0.84 | LCK (0.85) | LCKKDRLYNSRCINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | claimed |
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | claimed |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-10-16 | — | — | US | claimed |
| EP-1899329-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC A Delware Limited Liability Company (BM) | 2008-03-19 | — | — | EP | claimed |
| WO-2007005673-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-01-11 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| US-8426404-B2 | e.g. 3-[1-(6-Amino-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-benzamide; receptor and non-receptor tyrosine kinases and serine/threonine kinases inhibitor; antiproliferative agent; immune and nervous system disorders | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | disclosed |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-10-16 | — | — | US | disclosed |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-10-16 | — | — | US | disclosed |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-10-16 | — | — | US | disclosed |
| EP-1899329-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC A Delware Limited Liability Company (BM) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007005673-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | LCK 1172/4885KDR 2782/4885LYN 1453/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | LCK 1172/4885KDR 2782/4885LYN 1453/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | LCK 1172/4885KDR 2782/4885LYN 1453/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | LCK 1172/4885KDR 2782/4885LYN 1453/4885 |
| US-20080255112-A1 | Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors | BMX, FYN, BRSK2 | LCK 14/4885KDR 175/4885LYN 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.